Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2018-06-01
2019-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gut Hormones and Bone Remodeling in Humans (KS-2)
NCT03573934
Investigation of GLP-2 Mechanism of Action (GA-8)
NCT03159741
Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19
NCT03867656
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT01079624
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLP-2
Glucagon-Like Peptide-2 (GLP-2)
Glucagon-Like Peptide-2 (GLP-2)
Glucagon-Like Peptide-2 (GLP-2) injection.
GIP
Glucose-dependent Insulinotropic polypeptide (GIP)
Glucose-dependent insulinotropic polypeptide (GIP)
Glucose-dependent insulinotropic polypeptide (GIP) injection.
GLP-2+GIP
GLP-2+GIP
GLP-2+GIP
GLP-2+GIP injection.
Placebo
Placebo
Placebo
Placebo injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucagon-Like Peptide-2 (GLP-2)
Glucagon-Like Peptide-2 (GLP-2) injection.
Glucose-dependent insulinotropic polypeptide (GIP)
Glucose-dependent insulinotropic polypeptide (GIP) injection.
GLP-2+GIP
GLP-2+GIP injection.
Placebo
Placebo injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
80 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hvidovre University Hospital
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kirsa Skov-Jeppesen
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hvidovre University Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCPH-KS-3-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.